Pancreatic Ductal Adenocarcinoma: Molecular Pathology and Predictive Biomarkers

Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor prognosis due to the lack of methods or biomarkers for early diagnosis and its resistance to conventional treatment modalities, targeted therapies, and immunotherapies. PDACs are a heterogenous group of malignant epithelial neoplasms with...

Descripción completa

Detalles Bibliográficos
Autores principales: Taherian, Mehran, Wang, Hua, Wang, Huamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563270/
https://www.ncbi.nlm.nih.gov/pubmed/36231030
http://dx.doi.org/10.3390/cells11193068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563270/
https://www.ncbi.nlm.nih.gov/pubmed/36231030
http://dx.doi.org/10.3390/cells11193068

Ejemplares similares